Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). VEGF is a protein that promotes the growth of new blood vessels. While this benefits wound healing, it can be harmful in diseases where abnormal blood vessel growth is problematic. By inhibiting VEGF, Bevacizumab can prevent the formation of these abnormal blood vessels, thereby controlling the disease.
Conditions Treated by Bevacizumab
Age-Related Macular Degeneration (AMD): Bevacizumab helps slow the progression of wet AMD by reducing abnormal blood vessel growth and leakage in the retina.
Diabetic Retinopathy: This condition, caused by high blood sugar levels, leads to damage in the retinal blood vessels. Bevacizumab can help reduce swelling and improve vision.
Retinal Vein Occlusion: Blockage of the veins in the retina can lead to swelling and vision loss. Bevacizumab can reduce swelling and restore vision.
Neovascular Glaucoma: This type of glaucoma is associated with the growth of new, abnormal blood vessels in the eye, leading to increased eye pressure. Bevacizumab can help reduce these blood vessels and manage glaucoma.
